Population-based input function for TSPO quantification and kinetic modeling with [11C]-DPA-713

Abstract Introduction Quantitative positron emission tomography (PET) studies of neurodegenerative diseases typically require the measurement arterial input functions (AIF), an invasive and risky procedure. This study aims to assess reproducibility [ 11 C]DPA-713 PET kinetic analysis using population-based function (PBIF). The final goal is possibly eliminate need for AIF. Materials methods Eighteen subjects including six healthy volunteers (HV) twelve Parkinson disease (PD) from two C]-DPA-713 were included. Each subject underwent 90 min dynamic imaging. Five a test-retest scan within same day repeatability parameters. Kinetic modeling was carried out Logan total volume distribution ( V T ) model. For each data set, performed patient-specific AIF (PSAIF, ground-truth standard) then repeated PBIF. PBIF generated leave-one-out method remaining 17 after normalizing PSAIFs by 3 techniques: (a) Weight ×Dose Injected , (b) area under curve (AUC), (c) ×AUC. variability in measured with PSAIF, study, determined selected brain regions (white matter, cerebellum, thalamus, caudate, putamen, pallidum, brainstem, hippocampus, amygdala) Bland-Altman normalization techniques. Similarly, all subjects, variabilities due use assessed. Results showed systematic bias between test retest studies. corresponding mean 95% limits agreement (LOA) studied 30% ± 70%. Comparing PBIF- PSAIF-based estimate regions, significant difference results three techniques existed structures except brainstem P -value = 0.095). % LOA −10% ±45% ; +8% ±50% AUC; +2% 38% In cases, ×AUC yielded smallest (% ±2%; ±38% regions). Estimating PBIF-kinetics PSAIF based on groups (HV/PD) genotype (MAB/HAB), average values obtained insignificantly higher than (%difference 4.53%, 0.73 HAB; %difference 0.73%, 0.96 MAB). also tends overestimate PD HV HAB 32.33% versus 13.28%) underestimate it MAB 6.84% 20.92%). Conclusions are reproducible PBIF, that Therefore, assessed PBIF-based clinically feasible can be alternative PSAIF.